Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

Aims Anthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and
remains an important limitation of anthracycline‐based chemotherapy. In various genetic …

Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of
anthracycline therapy. Identification of genes and genetic variants associated with AIC risk …

Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use
in children was contraindicated by the EMA over concerns of increased risk of infection …

Anthracyclines (doxorubicin, daunorubicin, epirubicin, and idarubicin) are among the most
potent chemotherapeutic agents and have truly revolutionized the management of childhood …

Anthracyclines are an integral part of chemotherapy regimens used to treat a variety of
childhood-onset and adult-onset cancers. However, the development of cardiac dysfunction …

There are over 15 million survivors of cancer in the United States whose rates of frailty, an
aging phenotype, range from just under 10% to over 80%. Frailty impacts not only disease …

Simple Summary The effectiveness and safety of the anti-cancer agent doxorubicin
(anthracycline group medicine) depend on the metabolism and retention of the drug in the …

During the last few decades, pediatric acute lymphoblastic leukemia (ALL) cure rates have
improved significantly with rates exceeding 90%. Parallel to this remarkable improvement …

Chemotherapy-related cardiac dysfunction is a significant side effect of anticancer treatment.
Risk stratification is based on clinical-and treatment-related risk factors that do not …